Her first contact with mental-health services occurred at the age of 22 years, when she presented following a weekend poly-substance binge, including MDMA ('ecstasy'), other amphetamines and marijuana, waking one day with complex multimodal visual hallucinations and distortions. She attracted diagnoses of drug-induced psychosis and schizophrenia. She was unsuccessfully treated for three months with risperidone, which reportedly exacerbated her symptoms. Six months later, she received a tentative diagnosis of occipital lobe epilepsy by a neurologist following repeat electroencephalograms (EEGs) demonstrating bilateral occipitotemporal epileptiform discharges. She was subsequently commenced on levatiracetam, which was ceased three days later due to worsening of symptoms. She did not follow-up with mental-health services or neurology thereafter. Her distressing symptoms persisted for 18 months, despite refraining from recreational drug use, leading to depressive symptoms, severe anxiety and relationship breakdown. Her perceptual disturbances began to improve two months after commencement on lamotrigine 50 mg daily by a general practitioner, in light of her putative diagnosis of occipital epilepsy. She remained symptom free for three years, finished an undergraduate degree, relocated to study medicine and had significant sporting achievements.
The recurrence of symptoms occurred spontaneously one night while out with friends. She described symptoms comparable to 'being stuck on a bad trip', with distortion and misinterpretation of existing objects in space (e.g. her arm seeming three times as long, and specks of dust on the ground appeared abnormally obvious), the false perception of movement in peripheral visual fields, halos
The trip of a lifetime: hallucinogen persisting perceptual disorder around objects, intensified lights, after-images, depersonalisation and derealisation. She described heightened senses of hearing, taste and touch whilst having a blunted pain threshold. These experiences were intensified by higher levels of stimulation, such that she reported that exposure to a television screen was intolerable.
No acute trigger was identified. She had two alcoholic drinks and denied intentional drug use. The onset coincided with a period of heightened workload at university and reduced sleep. She maintained full insight into her symptoms. She did not exhibit psychotic symptoms. However, she reported a lowered mood and heightened anxiety as a result of her distressing experiences. The symptoms interfered with her functioning, as she was unable to tolerate high levels of stimulus or navigate traffic.
Following her relapse in hallucinations, the patient sought help through several emergency departments. Following a brief psychiatric admission, she was reviewed in general adult psychiatry outpatients, prompting a range of investigations. Basic blood tests, neurological exam, magnetic resonance imaging, EEG and neuropsychiatric and visual testing were normal. Files from her initial episode were reviewed, and a unifying diagnosis of hallucinogen persisting perceptual disorder (HPPD) was made. Lamotrigine was increased to 100 mg daily. Her symptoms improved after two weeks and were resolved over a period of three months.
Discussion
Since it was first described by Eisner and Cohen 1 in 1964, the phenomenology of HPPD remains poorly understood, and the literature is limited to case reports and observational studies. Incidence is unknown. According to the DSM 5, 2 HPPD is characterised mainly by perceptual disturbances, taking the following shapes or forms: geometric hallucinations, false perceptions of movement in the peripheral field images, flashes of colour, intensified colours, trails of images of moving objects, positive afterimages, halos around objects, macropsia and micropsia. In contrast to psychosis, there is no paranoid misinterpretation of these abnormal perceptions in HPPD sufferers, and full insight is maintained before, during and after the episode. Lerner 3 has more recently further distinguished HPPD-II from HPPD-I (a non-distressing, benign 'flashback' or 'free trip') as a chronic, recurrent, trigger-precipitated or spontaneous, slowly reversible or irreversible, and highly distressing visually pervasive experience, reminiscent of acute hallucinogen intoxication. It often leads to substantial morbidity and co-morbid psychiatric disorders. LSD use has been more widely associated with the development of this condition. However, it has also been associated with psilocybin, mescaline, cannabis, MDMA, phencyclidine, dextromethorphan and ketamine. 3 Upon resolution of the symptoms, a latent period lasting from days to years may precede the onset of the return of the visual imagery, with or without a recognised trigger. 3 Although not fully understood, reported triggers include existing mental disorders such as anxiety, mood and sleep disturbance, entering a dark environment, pregnancy and post-partum states, flashing car or neon lights, exposure to noise, and exercise. 3 According to unpublished data referred to in a clinical review by Lerner et al., 3 some patients show benefit from various SSRIs, low-dose olanzapine, quetiapine, amisulpride, aripiprazole and asenapine, and antiepileptic agents such as valproic acid, carbamazepine, oxycarbamazepine, gabapentin, topiramate or levetiracetam. Lamotrigine has been reported as useful, likely by inhibiting the glutamate-mediated excitatory neurotransmission thought to be involved in the pathophysiology of HPPD. 4 At one point, a diagnosis of occipital lobe epilepsy was considered following two abnormal EEGs, suggestive but not diagnostic of occipital lobe epilepsy in conjunction with a raft of symptoms, some of which are consistent with occipital seizures. An electrophysiology study by Abraham and Duffy 5 demonstrated that HPPD patients exhibit isolated occipital disinhibition and regional coherence upon eye closure, a state known to facilitate hallucinatory experiences, with similarities to inter-ictal and ictal epileptic foci.
Implications for clinical practice
Patients with perceptual disturbance can present in various clinical settings, and HPPD is an under-recognised diagnostic possibility. Delayed or misdiagnosis prolongs profound functional impairment and social decline, and predisposes the patient to the development of anxiety and depression and related increased risk of suicide.
Studies are needed to understand further the pathophysiology of HPPD and its associations with occipital lobe epilepsy, and to evaluate the efficacy of medications in order to recognise and treat this condition appropriately.
